In a report released yesterday, David Amsellem from Piper Jaffray reiterated a Hold rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $44. The company’s shares closed yesterday at $48.70.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -0.9% and a 45.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Supernus Pharmaceuticals with a $56.60 average price target.
See today’s analyst top recommended stocks >>
Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $30.74 million. In comparison, last year the company had a net profit of $17.37 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
